Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.38 |
| ▸ | IGF1R | P08069 | 4/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696570 | 1.00 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL2014177 | 1.00 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| Hydrochloric Acid SCHEMBL4110597 | 0.99 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL2012993 | 0.96 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL4110855 | 0.96 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL15589776 | 0.96 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL13696569 | 0.96 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL2011047 | 0.96 | HRH4 (0.38) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL2011401 | 0.95 | HRH4 (0.41) | HRH4CXCR4ALKIGF1RGPBAR1 | |
| SCHEMBL13696535 | 0.95 | HRH4 (0.41) | HRH4CXCR4ALKIGF1RGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | claimed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | HRH4 152/4885CXCR4 1/4885ALK 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.